vs
Side-by-side financial comparison of Dexcom (DXCM) and RENAISSANCERE HOLDINGS LTD (RNR). Click either name above to swap in a different company.
RENAISSANCERE HOLDINGS LTD is the larger business by last-quarter revenue ($2.2B vs $1.3B, roughly 1.7× Dexcom). RENAISSANCERE HOLDINGS LTD runs the higher net margin — 23.5% vs 21.2%, a 2.3% gap on every dollar of revenue. On growth, Dexcom posted the faster year-over-year revenue change (21.6% vs -36.8%). Over the past eight quarters, Dexcom's revenue compounded faster (12.0% CAGR vs -11.9%).
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
RenaissanceRe Holdings Ltd is a Bermudian provider of reinsurance, insurance and other related business services. The company operates in reinsurance, insurance and ventures.
DXCM vs RNR — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $2.2B |
| Net Profit | $267.3M | $515.8M |
| Gross Margin | 62.9% | — |
| Operating Margin | 25.6% | — |
| Net Margin | 21.2% | 23.5% |
| Revenue YoY | 21.6% | -36.8% |
| Net Profit YoY | 153.6% | 72.6% |
| EPS (diluted) | $0.67 | $6.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | $2.2B | ||
| Q4 25 | $1.3B | $3.0B | ||
| Q3 25 | $1.2B | $3.2B | ||
| Q2 25 | $1.2B | $3.2B | ||
| Q1 25 | $1.0B | $3.5B | ||
| Q4 24 | $1.1B | $2.3B | ||
| Q3 24 | $994.2M | $4.0B | ||
| Q2 24 | $1.0B | $2.8B |
| Q1 26 | $267.3M | $515.8M | ||
| Q4 25 | $267.3M | $760.5M | ||
| Q3 25 | $283.8M | $916.5M | ||
| Q2 25 | $179.8M | $835.4M | ||
| Q1 25 | $105.4M | $170.0M | ||
| Q4 24 | $151.7M | $-189.7M | ||
| Q3 24 | $134.6M | $1.2B | ||
| Q2 24 | $143.5M | $503.9M |
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | — | ||
| Q3 25 | 60.5% | — | ||
| Q2 25 | 59.5% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 59.7% | — | ||
| Q2 24 | 62.4% | — |
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | 42.5% | ||
| Q3 25 | 20.1% | 46.3% | ||
| Q2 25 | 18.4% | 41.8% | ||
| Q1 25 | 12.9% | -2.0% | ||
| Q4 24 | 17.0% | -3.6% | ||
| Q3 24 | 15.3% | 43.7% | ||
| Q2 24 | 15.7% | 25.0% |
| Q1 26 | 21.2% | 23.5% | ||
| Q4 25 | 21.2% | 25.6% | ||
| Q3 25 | 23.5% | 28.7% | ||
| Q2 25 | 15.5% | 26.1% | ||
| Q1 25 | 10.2% | 4.9% | ||
| Q4 24 | 13.6% | -8.3% | ||
| Q3 24 | 13.5% | 29.8% | ||
| Q2 24 | 14.3% | 17.8% |
| Q1 26 | $0.67 | $6.57 | ||
| Q4 25 | $0.67 | $16.16 | ||
| Q3 25 | $0.70 | $19.40 | ||
| Q2 25 | $0.45 | $17.20 | ||
| Q1 25 | $0.27 | $3.27 | ||
| Q4 24 | $0.37 | $-3.76 | ||
| Q3 24 | $0.34 | $22.62 | ||
| Q2 24 | $0.35 | $9.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $917.7M | $1.6B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.7B | $4.3B |
| Total Assets | $6.3B | $53.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $917.7M | $1.6B | ||
| Q4 25 | $917.7M | $1.7B | ||
| Q3 25 | $1.8B | $1.7B | ||
| Q2 25 | $1.2B | $1.4B | ||
| Q1 25 | $904.9M | $1.6B | ||
| Q4 24 | $606.1M | $1.7B | ||
| Q3 24 | $621.2M | $1.6B | ||
| Q2 24 | $939.2M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $1.9B | ||
| Q3 24 | — | $1.9B | ||
| Q2 24 | — | $2.0B |
| Q1 26 | $2.7B | $4.3B | ||
| Q4 25 | $2.7B | $11.6B | ||
| Q3 25 | $2.7B | $11.5B | ||
| Q2 25 | $2.6B | $10.8B | ||
| Q1 25 | $2.3B | $10.3B | ||
| Q4 24 | $2.1B | $10.6B | ||
| Q3 24 | $2.0B | $11.2B | ||
| Q2 24 | $2.4B | $10.2B |
| Q1 26 | $6.3B | $53.7B | ||
| Q4 25 | $6.3B | $53.8B | ||
| Q3 25 | $7.5B | $54.5B | ||
| Q2 25 | $7.3B | $54.7B | ||
| Q1 25 | $6.8B | $53.6B | ||
| Q4 24 | $6.5B | $50.7B | ||
| Q3 24 | $6.4B | $52.8B | ||
| Q2 24 | $6.8B | $51.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.19× | ||
| Q2 25 | — | 0.21× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.17× | ||
| Q2 24 | — | 0.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
